AbbVie (ABBV)
(Delayed Data from NYSE)
$195.22 USD
+6.20 (3.28%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $194.51 -0.71 (-0.36%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, AbbVie Inc. has a PEG ratio of 1.41 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.24.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABBV 195.22 +6.20(3.28%)
Will ABBV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABBV
Economy Heating Up on PCE for June
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
PCE Comes in Warmer Than Expected
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for ABBV
Over 75% of companies surpass EPS expectations this week: Earnings Scorecard
AbbVie (ABBV) Lifts Full-Year EPS Guidance Following Strong Q2
Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Nuclear Threats, Trump Fires Labor Statistics Chief, Fed Governor Resigns And More: This Week In Politics